PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Mise à jour : Il y a 4 ans
Référence : NCT00567840

Femme et Homme

Extrait

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 200, 600, 1000 and 1200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis. A control group will receive standard TB treatment.


Critère d'inclusion

  • Pulmonary tuberculosis

Liens